Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD33 + status confers therapeutic sensitivity to Cytarabine, Daunorubicin, Gemtuzumab ozogamicin in patients with Acute Myeloid Leukemia.
This statement is based on a regulatory approval from the Health Canada:
Mylotarg (gemtuzumab ozogamicin for injection) is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia.